Behavioral tolerance to and withdrawal from multiple fluxetine administration

References

• Baldessarini R. J., Marsh E. R., Kula N. S. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Research 1992; 579: 152–156
   PubMed Web of Science ®Google Scholar
• Benloucif S., Galloway M. P. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. European Journal of Pharmacology 1991; 200: 1–8
   PubMed Web of Science ®Google Scholar
• Bourchard R. H., Pourcher E., Vincent P. Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry 1989; 146: 1352–1353
   Google Scholar
• Callaway C. W., Johnson M. P., Gold L. H., Nichols D. E., Geyer M. Ampetramine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology 1991; 104: 293–301
   PubMed Web of Science ®Google Scholar
• Callaway C. W., Wing L. L., Nichols D. E., Geyer M. A. Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release. Psychopharmacology 1993; 111: 169–178
   Google Scholar
• Cervo L., Grignaschi G., Samanin R. The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test. European Journal of Pharmacology 1990; 178: 129–133
   PubMed Web of Science ®Google Scholar
• Chen N. H., Reith M. E. Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely-moving rats: a microdialysis study on monoamine interrelationships. Journal of Neurochemistry 1994; 63: 1701–1713
   PubMed Web of Science ®Google Scholar
• Coulter D. M., Pillans P. I. Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry 1995; 152: 122–125
   Web of Science ®Google Scholar
• Cunningham K. A., Callahan P. M. Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 1991; 104: 177–180
   Google Scholar
• Dilsaver S. C. Antidepressant withdrawal syndromes: phenomenology and pathophysiology. Acta Psychiatrica Scandinavica 1989; 79: 113–117
   PubMedGoogle Scholar
• Dilsaver S. C., Greden J. F. Antidepressant withdrawal phenomena. Biological Psychiatry 1984; 19: 237–256
   Google Scholar
• Gardier A. M., Lepoul E., Trouvin J. H., Chanut E., Dessalles M. C., Jacuot C. Changes in Dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sciences 1993; 54: PL51–56
   Google Scholar
• Gaytan O., Ghelani D., Martin S., Swann A., Dafny N. Dose response characteristics of methylphenidate on different indeces of rats' locomotor activity at the beginning of the dark cycle. Brain Research, (in press)
   Google Scholar
• Grunberg N. E. Overview: biological processes relevant to drugs of dependence. Addiction 1994; 89: 1443–1446
   Google Scholar
• Jacobs B. L. An animal behavioral model for studying central serotonergic synapses. Life Sciences 1976; 19: 777–786
   PubMed Web of Science ®Google Scholar
• Jacobs B. L., Klemfuss H. Brain stem and spinal cord mediation of a serotonergic behavioral syndrome. Brain Research 1975; 100: 450–457
   Google Scholar
• Kennedy A. J., Gibson E. L., O'Connell M. T., Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioral responses to mCPP. Psychopharmacology 1993; 113: 262–268
   Google Scholar
• Kennett G. A., Lightowler S., De Biasi V., Stevens N. C., Wood M. D., Tulloch I. F., Blackburn T. P. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 1994; 33: 1581–1588
   PubMedGoogle Scholar
• Kriess D. S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. Journal of Pharmacology & Experimental Therapeutics 1995; 274: 866–876
   Google Scholar
• Le Poul E., Lima L., Laporte A. M., Even C., Doucet E., Fattaccini C. M., Laaris N., Hamon N., Hamon M., Lanfumey L. Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine. Encephale 1995; 21: 123–132
   Google Scholar
• Li Q., Levy A. D., Cabrera T. M., Brownfield M. S., Battaglia G., Van de Kar L. D. Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT 1A agonist 8-OH-DPAT, in male rats. Brain research 1993; 630: 148–156
   Google Scholar
• Lucki I., Frazer A. Changes in behavior associated with serotonin receptors following repeated treatment with antidepressant drugs. Behavioral Pharmacology: The Current Status, I. P. Daily, U. Stink. Alan R. Liss, New York 1985; 339–357
   Google Scholar
• Lucki I., Nobler M. S., Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. Journal of Pharmacology & Experimental Therapeutics 1984; 228: 133–139
   PubMed Web of Science ®Google Scholar
• Meert T. F. Effects of various serotonergic agents on alcohol intake and alcohol preference in wistar rats selected at two different levels of alcohol preference. Alcohol & Alcoholism 1993; 28: 157–170
   Google Scholar
• Perry K. W., Fuller R. W. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sciences 1992; 50: 1683–90
   Google Scholar
• Porrino L. J., Ritz M. C., Goodman N. L., Sharpe L. G., Kuhar M. J., Goldberg S. R. Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sciences 1989; 45: 1529–1535
   PubMed Web of Science ®Google Scholar
• Prisco S., Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurons in the ventral tegmental. British Journal of Pharmacology 1995; 116: 1923–1931
   PubMed Web of Science ®Google Scholar
• Rapport D. J., Calabrese J. R. Tolerance to fluoxetine. Journal of Clinical Psychopharmacology 1993; 13: 361
   Google Scholar
• Tate J. L. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine (letter). American Journal of Psychiatry 1989; 146: 399–400
   PubMed Web of Science ®Google Scholar
• Tinsley J. A., Olsen M. W., Laroche R. R., Palmen M. A. Fluoxetine abuse. Mayo Clinic-Proceedings 1994; 69: 166–168
   Google Scholar
• Ulrichesen J., Partilla J. S., Dax E. M. Long-term administration of m-chlorophenylpiper-azine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion. Psychopharmacology 1992; 107: 229–235
   Google Scholar
• Wong D. T., Bymaster F. P., Engleman E. A. Prozac (fluoxetine, Lilly 110140), the firs selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life sciences 1995; 57: 411–441
   PubMed Web of Science ®Google Scholar
• Zemlan F. P., Garver D. L. Depression and antidepressant therapy: receptor dynamics. Progress in Neuro-psychopharmacology & Biological Psychiatry 1990; 14: 503–523
   Google Scholar